Substantial Improvement in a Nerve Conduction Study of Lymphoma-associated Demyelinating Neuropathy Treated by Intravenous Immunoglobulin and Chemotherapy

A 64-year-old woman with lymphoma-associated demyelinating neuropathy was treated by 6 cycles of R-CHOP with intravenous immunoglobulin in the first 2 cycles. We noted substantial improvement in the findings of a nerve conduction study (NCS) after the first cycle, followed by more protracted improve...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2018/12/01, Vol.57(23), pp.3467-3472
Main Authors: Iemura, Tomoki, Oba, Akifumi, Matsui, Masashi, Mano, Chihiro, Kawabata, Norihiro, Horisawa, Yoshihito, Miyahara, Yasuko, Itoh, Mitsuru
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
B-cell lymphoma
Case Report
Chemotherapy
Cyclophosphamide - therapeutic use
Demyelinating Diseases - drug therapy
Demyelinating Diseases - etiology
Demyelinating Diseases - physiopathology
Demyelination
Doxorubicin - therapeutic use
Etiology
Female
Humans
Immunoglobulins
Immunoglobulins, Intravenous - therapeutic use
Internal medicine
Intravenous administration
Lymphoma
Lymphoma, B-Cell - complications
Lymphoma, B-Cell - drug therapy
lymphoma-associated demyelinating neuropathy
Middle Aged
Nerve conduction
nerve conduction study
Neural Conduction - physiology
Neuropathy
Optimization
Placebo effect
Polyneuropathies - drug therapy
Polyneuropathies - etiology
Polyneuropathies - physiopathology
Prednisone - therapeutic use
Vincristine - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 64-year-old woman with lymphoma-associated demyelinating neuropathy was treated by 6 cycles of R-CHOP with intravenous immunoglobulin in the first 2 cycles. We noted substantial improvement in the findings of a nerve conduction study (NCS) after the first cycle, followed by more protracted improvement during the second to sixth cycles. The improvement of the neurological symptoms paralleled the findings of the NCS. Our case provides important information for understanding the etiology and optimization of treatments for lymphoma-associated demyelinating neuropathy.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.0678-17